Otonomy, Inc.

OTCPK:OTIC Stock Report

Market Cap: US$582.5k

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Otonomy Balance Sheet Health

Financial Health criteria checks 3/6

Otonomy has a total shareholder equity of $21.4M and total debt of $16.1M, which brings its debt-to-equity ratio to 75.4%. Its total assets and total liabilities are $57.5M and $36.1M respectively.

Key information

75.38%

Debt to equity ratio

US$16.13m

Debt

Interest coverage ration/a
CashUS$40.15m
EquityUS$21.40m
Total liabilitiesUS$36.13m
Total assetsUS$57.53m

Recent financial health updates

Analysis Article • Feb 02

Is Otonomy (NASDAQ:OTIC) Using Debt In A Risky Way?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Recent updates

Seeking Alpha • Aug 01

Otonomy crashes 73% as mid-stage trial for tinnitus candidate fails

The shares of neurology focused Otonomy (NASDAQ:OTIC) plunged ~73% in the pre-market Monday after the company said its Phase 2 trial for OTO-313 did not demonstrate a clinically meaningful benefit for OTO-313 compared to placebo in hearing disorder tinnitus. "These results were unexpected with a much higher placebo response than observed in the prior Phase 1/2 study,” Chief Executive David A. Weber noted, adding that the company would discontinue further development of OTO-313 and take other steps to extend cash runway. This is a developing story. Check back for more updates.
Seeking Alpha • Jul 25

Otonomy GAAP EPS of -$0.19 beats by $0.01

Otonomy press release (NASDAQ:OTIC): Q2 GAAP EPS of -$0.19 beats by $0.01. Cash Position: Cash, cash equivalents, and short-term investments totaled $53.1 million as of June 30, 2022, compared to $77.4 million as of December 31, 2021. Outlook: Financial Guidance: Otonomy expects that GAAP operating expenses for 2022 will be in the range of $52-$54 million, and that non-GAAP operating expenses will be in the range of $42-$44 million.
Seeking Alpha • Apr 04

Otonomy: Hearing Loss And Tinnitus Data In 2022

Data for OTO-413 in hearing loss is due early in Q2 2002. Data for OTO-313 in tinnitus is due mid-2022. Tinnitus and hearing loss are indications with no FDA-approved medicines and are each billion-dollar markets. Precedent suggests developing therapeutics for these indications is an extremely difficult task.
Analysis Article • Jun 16

Shareholders Will Probably Hold Off On Increasing Otonomy, Inc.'s (NASDAQ:OTIC) CEO Compensation For The Time Being

Shareholders of Otonomy, Inc. ( NASDAQ:OTIC ) will have been dismayed by the negative share price return over the last...
Analysis Article • Feb 02

Is Otonomy (NASDAQ:OTIC) Using Debt In A Risky Way?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Dec 11

Are Institutions Heavily Invested In Otonomy, Inc.'s (NASDAQ:OTIC) Shares?

A look at the shareholders of Otonomy, Inc. ( NASDAQ:OTIC ) can tell us which group is most powerful. Institutions will...

Financial Position Analysis

Short Term Liabilities: OTIC's short term assets ($43.9M) exceed its short term liabilities ($25.3M).

Long Term Liabilities: OTIC's short term assets ($43.9M) exceed its long term liabilities ($10.9M).

Debt to Equity History and Analysis

Debt Level: OTIC has more cash than its total debt.

Reducing Debt: OTIC's debt to equity ratio has increased from 0% to 75.4% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OTIC has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: OTIC has less than a year of cash runway if free cash flow continues to grow at historical rates of 16.3% each year.

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/04/13 11:08
End of Day Share Price 2023/04/11 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Otonomy, Inc. is covered by 9 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aaron GalBernstein
Sumant Satchidanand KulkarniBofA Global Research
Charles DuncanCantor Fitzgerald & Co.